Business Context and Reporting Period
This Form 6-K filing by Apollomics Inc. covers the month of April 2026. The report discloses a material definitive agreement and related-party transaction entered into on March 30, 2026.
Key Financial Metrics
The filing does not provide standard financial statements, revenue, profit, cash flow, or margin data. The primary financial metric disclosed is a new debt instrument:
- Debt Raised: $2,000,000 principal amount via a Convertible Promissory Note.
- Interest Rate: 0% per annum.
- Security Status: Unsecured.
- Liquidity Impact: Proceeds are designated for working capital and general corporate purposes to support ongoing clinical operations.
Material Changes
The material change reported is the execution of a bridge loan with Mr. Hung-Wen (Howard) Chen, the Company's Chairman and Chief Executive Officer. This transaction was reviewed by the Audit Committee and approved by the Board of Directors, with Mr. Chen abstaining from the vote.
Guidance, Outlook, and Terms
The filing outlines specific terms for the convertible note rather than providing forward-looking financial guidance:
- Automatic Conversion: The note converts into equity upon the closing of the Company's next equity financing raising at least $10,000,000. The conversion price will be 80% of the lowest per-share purchase price in that financing.
- Maturity Date: Eighteen months from issuance (approximately September 2027).
- Alternative Conversion: If not converted earlier, the holder may elect to convert into Class A ordinary shares based on the average closing price of the ten trading days preceding the Maturity Date.
- Risks: The transaction is a related-party transaction involving an executive officer.
Investor Verification Checklist
- Verify the status of the Company's "Next Equity Financing" to determine if the $2,000,000 note will convert automatically.
- Confirm the dilution impact on existing shareholders if the note converts at 80% of the future financing price.
- Monitor the Company's cash burn rate to assess if the $2,000,000 bridge loan is sufficient to sustain clinical operations until the next financing or maturity.
- Review the Audit Committee's specific findings regarding the related-party transaction approval.